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APACHE = Acute Physiology and Chronic Health Evaluation; FID = functional iron deficiency; ICU = intensive care unit; IL = interleukin; IV =
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Introduction
Recent observational studies have shown that most patients
in the intensive care unit (ICU) become anemic within a few
days [1–3]. In Europe, approximately 37% of patients receive
transfusions and just over 70% of those remaining in the ICU
for longer than 7 days are transfused [1]. The CRIT Study
showed similar results in the United States [2]. A number of
factors contribute to this anemia, including the acute
inflammatory reaction typical of these patients [3,4]. Anemia
of inflammation has been clearly described in patients with
cancer, with chronic inflammatory disease and with chronic
infection [5–10]. This type of anemia is related to the release
of mediators that cause a blunted erythropoietic response
and an activation of red blood cell catabolism by macro-
phages. The inflammatory state also results in decreased
mobilization of iron stores from the reticuloendothelial system,
leading to the development and persistence of anemia
[5–10].
Special attention has been paid in recent years to limiting the
number of transfusions received by ICU patients. Limiting
blood collection[1] and restrictive transfusion thresholds[11]
are among the strategies that have been adopted for blood
conservation. Although the optimal dose of recombinant
human erythropoietin (rHuEPO) in the intensive care setting
has yet to be determined, its use constitutes another blood
conservation strategy [12,13]. Erythropoietin’s ability to
stimulate erythrocyte production is highly dependent on the
availability of iron. Understanding iron metabolism in this
patient population is important in order to act on the
mechanisms of and the causes of anemia in critically ill
patients. The decrease in iron availability seen in inflammatory
diseases may contribute to inadequate erythropoiesis in ICU
patients.
Is the iron metabolism imbalance seen in chronic
inflammatory states similar to that found in ICU patients? To
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Abstract
Critically ill patients frequently develop anemia due to several factors. Iron-withholding mechanisms
caused by inflammation contribute to this anemia. The iron metabolism imbalances described or
reported in all intensive care studies are similar to the values observed in anemia of inflammation. The
administration of iron could be useful in the optimization of recombinant human erythropoietin activity,
but this could be at the expense of bacterial proliferation. Since there is a lack of evidence to support
either oral or intravenous iron administration in intensive care patients, further studies are necessary to
determine the efficacy and safety of iron supplementation in conjunction with recombinant human
erythropoietin in critically ill patients. We review the mechanisms leading to iron sequestration in the
presence of inflammation. The present article also reviews the literature describing the iron status in
critically ill patients and explores the role of iron supplementation in this setting.
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what extent do these disturbances affect erythropoiesis and
the patient’s response to exogenous erythropoietin? Should
iron supplements be administered? The purpose of the
present article is to review the impact of inflammation on iron
status and to review the studies that describe iron
metabolism in ICU patients. We also explore the role of iron
supplementation in this setting.
Iron-withholding mechanisms in the presence
of inflammation
Most of the iron available for erythropoiesis comes from the
catabolism of senescent red blood cells by the macrophages
in the reticuloendothelial system [6–10]. The iron, trans-
ported by transferrin, binds to receptors on the surface of the
erythroblasts and is used in hemoglobin synthesis [6–10].
The iron also binds to apoferritin to produce iron stored in the
form of ferritin. Under normal conditions, there is a balance
between the iron transport paths and the iron stores [6–10].
Ferritin is an inflammatory protein (acute-phase reactant). The
synthesis of ferritin is increased by circulating cytokines such
as IL-1 and tumor necrosis factor. When these inflammation
mediators are present, iron stored in the form of ferritin tends
to increase and the mobilization of iron stored from the
reticuloendothelial system tends to decrease. The balance
between the amount of iron available for erythropoiesis and
the stored iron is disturbed (Fig. 1) [6–10]. Hypoferremia
rapidly sets in due to an increase in the iron-binding capacity
of ferritin, to the detriment of transferrin. The severity of the
hypoferremia depends on the severity of the underlying
inflammatory disease [6].
IL-1 also stimulates lactoferrin synthesis. Lactoferrin is a
circulating protein that binds iron with greater affinity than
transferrin [6,7,9]. In the presence of inflammation, iron
bound to lactoferrin is captured by the macrophages and is
then stored in the form of ferritin, thereby withholding iron
from the erythroid precursors (Fig. 1) [6,7,9]. The recent
demonstration that a novel protein, hepcidin, is greatly
upregulated in response to inflammation via IL-6 is yet
another potential mechanism of iron sequestration [14].
Hepcidin could be a central mediator of decreased iron
absorption through the gut and of sequestration of iron in
macrophages, and its structure has also shown homology to
naturally occurring antimicrobial proteins [14]. Changes
related to inflammation therefore lead to less iron bound to
transferrin and to less iron available for erythropoiesis [6–10].
This process has been hypothesized to have evolved as a
‘tug-of-war’ phenomenon resulting in an iron-deficient milieu
that would lead to compromised microorganism proliferation
(Fig. 1) [7,9].
Overall, these mechanisms result in a decrease in serum iron
<9µmol/l, in a decrease in transferrin levels <3 g/l and in a
decrease in the transferrin saturation percentage between
10% and 20%, with normal or elevated ferritin levels
>300 µg/l [8,10]. Elevated ferritin levels in inflammatory
states make it difficult to evaluate iron stores. However, a
patient presenting with a ferritin concentration >200 µg/l
probably does not have an iron deficiency, whereas a value
<30µg/l does indicate iron deficiency (ferritin levels between
30 and 200 µg/l in inflammatory conditions) [6,10].
In contrast with these iron-deprivation mechanisms, it seems
that iron deficiency could impair immune defense. Little
evidence is available on iron and its effects on direct
immunity. However, in vitro studies have suggested that iron
deficiency depresses some aspects of cell-mediated
immunity [15]. In a review of the literature, Oppenheimer
reported deleterious effects of iron deficiency on lymphocyte,
neutrophil and macrophage function [15]. Whether these
effects depend on the severity of iron deficiency is not known.
Not only iron deficiency but also iron overload seems to
impair polymorphonuclear leucocyte function, reducing phago-
cytic function and bacterial killing [16]. Data regarding iron
and its effect on the immune system are conflicting. More
studies are needed to clearly elucidate the role of iron on
immunity.
Iron metabolism in ICU patients
Inflammation is implicated in many critically ill disorders.
Indeed, clinical evidence of systemic inflammation is present
Figure 1
Decrease in iron recycling in the presence of inflammation: iron
metabolism in critically ill patients. Most of the iron available for
erythropoiesis comes from the catabolism of senescent red blood cells
(RBC) by the macrophages in the reticuloendothelial system. Under
normal conditions, there is a balance between the iron transport paths
and the iron stores: serum iron, 9–27 µmol/l; transferrin, 3–6 g/l;
transferrin saturation (sat.), 30–50%; ferritin, 50–150 µg/l. In the
presence of inflammation, the synthesis of ferritin is increased by IL-1
and by tumor necrosis factor (TNF). Hypoferremia rapidly sets in due to
an increase in the iron-binding capacity of ferritin to the detriment of
transferrin. IL-l also stimulates lactoferrin synthesis. Iron bound to
lactoferrin is captured by the macrophages and is stored in the form of
ferritin. Hepcidin could be a central mediator of iron sequestration in
macrophages. Grey arrows, pathways increased by inflammation;
broken arrows, pathways decreased by inflammation.358
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in almost all patients developing multiple organ dysfunction
syndrome, a common complication observed in critically ill
patients [17]. The severity of the host inflammatory response
is highly related to the development of multiple organ
dysfunction syndrome and is frequently seen in patients with
sepsis. The anemia of inflammation is a hypoproliferative
anemia defined by a low serum or plasma iron concentration
in the presence of adequate reticuloendothelial iron stores
[5]. It is possible that iron metabolism involved in the anemia
of chronic disease is similar to the anemia seen in critically ill
patients because of the presence of inflammatory mediators
in both conditions.
To describe iron metabolism in critically ill patients, a search
was performed on the MEDLINE database from 1966 to
December 2004 for articles describing iron metabolism in
adult critically ill patients. The term ‘critical illness’ was
combined with the terms ‘iron’, ‘erythropoiesis’ and ‘anemia’.
All English-language articles describing iron metabolism in
the ICU setting were retained. The bibliographies of these
articles were reviewed for additional references. Five
observational studies described iron metabolism in ICU
patients [3,18–21], and one study provided indicators of iron
status [22]. All studies described iron metabolism in a
population of nonbleeding, acutely ill patients. Studies on iron
metabolism mediators are summarized in Table 1.
Two studies described iron metabolism throughout the ICU
stay [3,18]. The earliest of these described the iron status in
critically ill surgical patients. In 1989, in a study involving 51
patients, Bobbio-Pallavicini and colleagues observed a
decrease in serum iron and elevated ferritin levels in more
than 75% of patients on their third day of hospitalization in
the surgical ICU [18]. Table 1 presents the variations in iron
metabolism indicators during intensive care for all patients.
Ferritin values remained abnormally elevated among all
patients during their stay in the ICU. Patients with sepsis
leading to multiple organ dysfunction syndrome had the
highest ferritin values. Indeed, among patients who
developed postoperative sepsis, there was a significant drop
in hemoglobin (107.3 g/l versus 125.7 g/l, P < 0.001), a
significant increase in ferritin levels (1585 µg/l versus
641 µg/l, P < 0.001) and a significant decrease in transferrin
(1.44 g/l versus 1.95 g/l, P < 0.001) compared with their
Table 1
Studies describing iron metabolism in intensive care unit (ICU) patients
Time of  Iron  Ferritin  Transferrin saturation  Transferrin 
Study measurement (µmol/l) (µg/l) (%) (g/l)
Reference value with inflammation [8,10] < 9 30–200 10–20 < 3
Surgical ICU patients [18] Week 1 4.1 652 12.8 1.7
Week 2 4.1 1234 11.9 1.5
Week 3 4.6 1536 13.4 1.4
Week 4 6.9 1367 18.7 1.4
Medical ICU patients ≥ 4 days [3] Days 1–2 4.8a 471a,b 16a 1.4a,c
Days 6–8 6.0a 767a,b 15a 1.3a,c
Days 13–15 6.5a 795a,b 22a 1.3a,c
Days 20–25 8.1a 774a,b 24a 1.4a,c
Days 31–40 7.8a 723a,b 20a 1.5a,c
Medical and surgical ICU patients [19] Days 2–3 4.9d 727b 16 Not reported
General ICU patients [21]
Functional iron deficiency Day 1 Not reported 342 Not reported Not reported
No functional iron deficiency Day 1 Not reported 292 Not reported Not reported
Multiple mechanical trauma patients [20] Day 1 9.5 832 Not reported 1.7c
Day 2 3.9 547 Not reported 1.7c
Day 4 3.4 466 Not reported 1.5c
Day 6 4.0 530 Not reported 1.6c
Day 9 5.0 842 Not reported 1.6c
Data presented as mean values, except a median values. b Ferritin (ng/ml or µg/ml). c Transferrin (mg/dl) multiplied by 0.01 to convert to transferrin
(g/l). d Iron (µg/dl) multiplied by 0.1791 to convert to iron (µmol/l).359
presepsis state. However, sepsis did not significantly affect
serum iron levels. When sepsis resolved, the transferrin and
hemoglobin values increased. Ferritin decreased dramatically
with sepsis resolution (1585 µg/l versus 472 µg/l, P < 0.001).
The incidence, severity, characteristics and causes of anemia
in 96 patients who had been in a medical ICU for longer than
3 days were assessed in the second study [3]. Fifteen
percent of the patients experienced acute bleeding, and 39%
of the patients were transfused during their stay in the ICU.
While they were in the ICU, 71 patients (74%) developed
anemia (hemoglobin <110 g/l) that could not be explained by
blood loss alone. Elevated ferritin values and decreased
transferrin saturation values were observed in these patients
(Table 1). During the first 2 weeks of the ICU stay, more than
50% of patients had abnormal serum iron concentrations.
These values continued to be observed for longer than
4 weeks, as reported in the study performed by Bobbio-
Pallavicini and colleagues [18]. Increased iron sequestration
secondary to inflammation could explain the increased ferritin
levels and the reduced serum iron concentration and
transferrin saturation observed in these studies.
Two other studies in critically ill patients reported their
observations on iron metabolism on the first few days of
admission [19,22]. Rodriguez and colleagues present iron
metabolism values for patients with hematocrit <38% on the
second or third day in the ICU [19]. These values come from
screening data for a study comparing rHuEPO administration
with placebo in surgical and medical ICU patients [23]. Of
the 184 patients screened for this study, 16 had transferrin
saturation <15% or ferritin <50 µg/l and were not included.
Eight patients had a vitamin B12 deficit or a folate deficit and
were also excluded. The remaining 160 patients were
included. The admitting diagnoses were pneumonia (24%),
respiratory diseases (21%) and trauma (15%). The values for
serum iron, ferritin and transferrin saturation for the 160
patients are comparable with values seen in anemia of
inflammation, and are presented in Table 1. The mean hemo-
globin at the beginning of the study was 103 ± 12 g/l.
Although these values were measured at baseline, prior to the
administration of the first dose of study medication, this study
was not designed to study iron metabolism in consecutive
patients.
The second study, conducted by Elliot and colleagues,
reported iron metabolism abnormalities in 25 ICU patients with
acute failure of at least one organ [22]. Patients with chronic
renal failure, coagulopathy or active bleeding were excluded. In
the majority of patients in the ICU for longer than 12 hours, they
found decreased mean serum iron levels (1.0–12.6 µmol/l),
increased mean ferritin levels (37–2376 µg/l) and decreased
mean transferrin levels (0.57–2.46 g/l). Ferritin values were
abnormally elevated (>300 µg/l) in 16 patients and were
greater than 1000 µg/l in three patients. Iron metabolism
imbalances set in fairly quickly after ICU admission, along
with the inflammatory process reflected by the increased
concentrations of IL-6 and C-reactive protein. The mean
hemoglobin at admission was between 80 and 110 g/l.
The anemia observed in the studies of Rodriguez and
colleagues and of Elliot and colleagues was not secondary to
active bleeding or coagulopathy because these etiologies
were exclusion criteria [19,22]. However, an abnormal iron
metabolism could have contributed to this disorder. Mean
values are not reported in the study of Elliot et al. and
therefore are not presented in Table 1. It should be noted that
the patients in this observational study received a daily
200 mg supplement of oral ferrous sulfate (or equivalent) that
may have affected the results.
Finally, patients admitted to the ICU for multiple trauma also
seem to quickly develop hypoferremia secondary to inflam-
mation. Iron metabolism in 23 severely traumatized patients
was evaluated by Hobisch-Hagen and colleagues [20]. On
admission to the ICU, they presented with an average
hemoglobin level of 100 g/l (68–129 g/l). Twelve hours after
admission to the ICU, ferritin levels were markedly elevated
(>300 µg/l). The elevated levels persisted beyond 1 week.
Reduced serum iron concentrations on the second day of
hospitalization were statistically significant, compared with
admission, and remained lower for longer than 1 week.
Serum transferrin was low and did not change during the ICU
stay. Indicators of iron status for this study are presented in
Table 1 and are compatible with iron parameters usually seen
in the presence of inflammation.
In summary, these observational studies all demonstrate that
critically ill patients present a decrease in the availability of
iron along with an elevation of ferritin levels. In light of the
data presented, iron metabolism in ICU patients seems to
behave in the same way as it does in chronic inflammatory
disease. The iron metabolism imbalances described or
reported in all of the studies are similar to the values
observed in anemia of inflammation. Indeed, elevated ferritin
>300 µg/l, serum iron <9 µmol/l, transferrin saturation
between 10% and 20%, and transferrin levels <3 g/l are
generally observed in critically ill patients (Table 1). Iron
metabolism disorders set in within the first few days. Ferritin
remained at particularly elevated levels throughout the ICU
stay, reflecting the inflammatory condition of these patients.
Iron metabolism disorders therefore probably contribute to
the anemia observed in ICU patients.
Functional iron deficiency
Patients with anemia of inflammation, unlike iron deficiency
anemia, may have normal iron stores but might present a
functional iron deficiency (FID). FID refers to the inability to
use iron efficiently for erythropoiesis, in spite of adequate iron
stores. FID may develop with rHuEPO therapy and might be a
cause of poor response. FID is observed in chronic dialysis
patients receiving rHuEPO. The increased erythropoiesis
Available online http://ccforum.com/content/8/5/356360
activity induced by rHuEPO exceeds the amount of functional
iron available. FID may also occur in inflammatory conditions
when the iron is locked away and stored by the
reticuloendothelial system, preventing the release of the iron
required for erythropoiesis. A decrease in transferrin
saturation will occur in spite of normal or elevated ferritin.
FID has been defined by the presence of more than 10%
hypochromic red blood cells. An observational study on the
prevalence of FID on admission to the ICU for 51 patients
was conducted by Patteril and colleagues [21]. A patient in
that study was considered to have a FID if more than 10% of
the red blood cells were hypochromic. Upon admission to the
ICU, 35% of patients (95% confidence interval, 22–48%)
presented FID. The mean Acute Physiology and Chronic
Health Evaluation (APACHE) II scores of patients with and
without FID were comparable. Anemia was no more severe
among patients with FID than in those without FID (average
hemoglobin concentration, 107 g/l versus 108 g/l,
respectively). The mean length of stay in the ICU was
statistically increased among patients with FID (7.6 days
versus 3.3 days, P < 0.0007). The severity of FID also
correlated with the duration of the ICU stay.
FID could thus reflect the severity of the critical illness.
However, FID was not associated with APACHE II scores
and no difference in the mortality was observed between the
two groups. This could of course be due to a lack of power,
and further studies are needed to determine whether FID in
critically ill patients is simply a marker of nutritional status or is
a predictor for outcome. Iron stores are difficult to evaluate in
the presence of inflammation because ferritin is frequently
increased. The ferritin values of both groups of patients are
presented in Table 1.
Should we supplement critically ill anemic
patients with iron?
Considering the physiopathology of the anemia of inflammation,
it is unlikely that iron supplementation would further stimulate
erythropoiesis unless iron deficiency is masked by elevated
ferritin levels [6,7]. Only one randomized open-label
prospective study evaluated erythropoietic response to the
administration of iron supplementation in anemic critically ill
patients [24]. In this study, all patients (36 patients) received
1 mg folic acid daily. One-third of the patients received no
additional therapy. The iron group (12 patients) received 20 mg
intravenous (IV) iron supplementation daily for 14 days. The
rHuEPO group (12 patients) received IV iron with 300 U/kg
rHuEPO every 2 days for 14 days. Compared with the levels in
the other two groups, the elevation in reticulocyte counts was
statistically significant only in the rHuEPO group. Reticulocyte
counts increased in the rHuEPO group from 56 ± 33 × 109/l to
a maximum of 189 ± 97 × 109/l on day 13. No such increase
was seen in the iron group. No significant difference was
observed between the three groups in terms of hemoglobin
concentration.
Iron supplementation with rHuEPO
Administration of rHuEPO generally makes it possible to
alleviate anemia secondary to chronic inflammatory disease.
A few studies have shown that rHuEPO administration also
stimulates erythropoiesis in ICU patients with acute inflam-
matory states [12,13]. A large-scale study recently demon-
strated that rHuEPO together with oral iron supplementation
reduced the need for blood transfusions in ICU patients [13].
The amplification of erythropoiesis that results from the
administration of rHuEPO increases the need for iron.
Consequently, rHuEPO must be used in conjunction with an
iron supplement to optimize the eryhropoietic response and
to prevent FID. Given the high prevalence of FID in ICU
patients [21], it would appear essential to provide iron
supplementation for critically ill patients receiving rHuEPO.
Oral supplementation such as that used recently by Corwin
and colleagues [13] may not be optimal for all ICU patients
because the gastrointestinal tract is not always functional and
iron absorption is poor and erratic. Moreover, decreased iron
gut absorption by increased hepcidin production and other
mechanisms (particularly related to the underlying condition
of the patient) may predispose to inadequacy of oral iron
therapy. Nevertheless, a significant reduction in transfusion
needs was shown in their study [13].
Whether iron supplementation is necessary in these patients
or whether the response might have been improved with IV
iron remain to be determined. Iron supplementation clearly
improves the response to rHuEPO. It has been shown that IV
iron administration with rHuEPO is beneficial for many
dialysis patients and has become standard therapy for several
patients [25]. Furthermore, administering an IV iron supple-
ment with rHuEPO could make it possible to optimize the
erythropoietic response in inflammatory states, as demon-
strated in patients with rheumatoid arthritis [26] and in
patients with Crohn disease [27]. IV iron supplementation in
the ICU setting may prove hazardous, however, given the
hemodynamic adverse effects that are possible with certain
formulations of parenteral iron and the risk to promote the
growth of bacteria.
Iron supplementation and risk of infection
Iron is an essential component of bacterial growth [9,28]. Iron
sequestration during inflammation could represent a defense
mechanism [9,28]. However, iron chelation with siderophores
allows bacterial proliferation in a reduced-iron environment
[9,28]. Iron administration could therefore, in theory, increase
the host susceptibility for bacterial infections.
No data on critically ill patients are available to support such a
hypothesis. The EPIBACDIAL study, performed in 988 patients
with chronic renal failure requiring hemodialysis, did not
observe a relationship between iron administration and
bacteremia (54.0% in those supplemented with iron versus
52.9% in those without, P = 0.88) [29]. The data from the
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EPIBACDIAL trial were revised by Hoen and colleagues to
evaluate the potential role of IV iron administration on the risk
of bacteremia [30]. High-frequency iron administration and
high-dose IV iron administration could be associated with an
increased incidence of bacteremia. The incidence also
increased if the patients were given rHuEPO (relative risk,
5.5; 95% confidence interval, 1.29–23.5). These data from
chronic renal failure patients could suggest a link between IV
iron administration and infection. IV iron administration to ICU
patients who are already infected could therefore be risky.
In the Corwin and colleagues’ study, oral iron supplemen-
tation was given with rHuEPO to all patients [13]. If oral iron
was not tolerated, patients received IV iron supplementation.
Despite the fact that oral iron administration did not appear to
produce deleterious effects in the Corwin and colleagues’
study, the safety of iron administration should be further
investigated before a widespread utilization of iron replace-
ment occurs in the ICU.
Conclusion
Six studies have so far described iron metabolism in critically
ill patients. A decrease in the availability of iron is generally
observed, along with elevated ferritin levels. In these patients,
iron metabolism is similar to that found in inflammatory
diseases and may contribute to the anemia observed in ICU
patients. Iron deficiency is difficult to evaluate in the presence
of inflammation. Future studies using a novel approach based
on hematologic indices would be useful [31]. Additional
studies are necessary to determine the utility of iron
supplementation alone in critically ill patients.
At the present time, there is a lack of evidence to support
either oral or IV iron administration in critically ill patients.
Further studies are needed to determine the safety of iron
supplementation in ICU patients, especially the link between
iron and clinical infectious risk. A large randomized study
comparing IV iron supplementation, oral iron supplementation
and no iron supplementation in rHuEPO-treated critically ill
patients would be of interest.
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